*LiquidScan®

ISOLATE RARE CELLS AND EXOSOMES – CTCs, TROPHOBLASTS, EVs

BioFluidica has created LiquidScan® as a unique fully automated system for isolating and enriching rare cells and exosomes from liquid biopsy samples. The system uses a microfluidic chip surfaced with antibodies targeting biomarkers of interest, creating the future of liquid biopsy.

LIQUIDSCAN® WORKFLOW

The BioFluidica LiquidScan hardware & software modules are integrated into the Hamilton Microlab STAR and STARlet liquid handling robot.

The LiquidScan Software controls loading the sample(s) onto the microfluidic chips, washing to remove background cells and cleavage and elution of captured cells or EVs from the chip.

The software creates a secure-loop system, two-pipette tips per chip, which dispense and aspirate simultaneously enabling relatively large volumes of liquid biopsy sample to be passed through the chip.

THE *LIQUIDSCAN SYSTEM

  • LiquidScan Microfluidic Chip Processing Module

  • LiquidScan Reagent Kit
    (with LiquidScan Microfluidic Chips surfaced with antibodies)

  • LiquidScan Software

  • LiquidScan installs on a Hamilton Microlab STARlet or STAR liquid handling robot
    (Contact us     regarding pre-owned, new or adding LiquidScan to one you already have)

*For Research Use Only

Consumables

LIQUIDSCAN REAGENT KITS

  • Reagent plate with contents ready to process 4 or 8 microfluidic chips

  • Microfluidic chips (4 or 8):

    • Antibody-surfaced sinusoidal chips for rare-cell capture or,
    • Antibody-surfaced pillar chips for exosome subpopulation capture

  • Sample tubes (8)

  • Waste tubes or re-process sample tubes (8)

PILLAR & SINUSOIDAL CHIPS

  • Microfluidic chip surface is tunable to isolate biomarkers of interest. Established for isolation of Exosomes in plasma and Rare cells in whole blood.

  • Release of isolated target analytes can be optimized for downstream applications.

  • Enzymatic release for evaluation of EV or Rare Cell surface markers or lyse on chip for nucleic acid or protein investigation.

Schedule a consultation with our research team to discuss your specific needs.

*LiquidScan is for Research Use Only

ABOUT BIOFLUIDICA

BioFluidica is a privately held biotechnology and liquid biopsy company. We have developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, extracellular vesicles (EVs; exosomes), and cfDNA, on one fully automated platform. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. We are expert consultants in exosome isolation, fetal cell (trophoblast)  isolation, CTC isolation, and next-generation liquid biopsy. We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients.